Lv3
348 积分 2022-04-19 加入
科研有趣，有趣科研
Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer
1个月前
已完结
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
3个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
3个月前
已完结
PCSK9 and cancer: Rethinking the link
4个月前
已完结
The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy
4个月前
已完结
Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors
4个月前
已完结
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience
4个月前
已完结
Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer
4个月前
已完结
Safe Anti-Programmed Cell Death-1 Rechallenge With Antibody Switching After Immune-Related Adverse Events: Brief Communication
4个月前
已关闭
Safe Anti-Programmed Cell Death-1 Rechallenge With Antibody Switching After Immune-Related Adverse Events: Brief Communication
4个月前
已关闭
皖公网安备34019202002308
